Trending...
- Are You Ready To Join Team GOAT Today?
- Ribbon-Cutting Ceremony Marks the Completion of TAJ Flooring, Inc. Warehouse Facility Expansion
- Chicago: MAYOR JOHNSON TRAVELS TO LONDON TO CHAMPION ECONOMIC GROWTH, GLOBAL BUSINESS, TOURISM & HOSPITALITY
~ Endotronix, Inc., a leading company in the field of heart failure treatment, has recently received Premarket Approval (PMA) from the U.S Food and Drug Administration (FDA) for their innovative Cordella™ Pulmonary Artery (PA) Sensor System. This approval marks a significant milestone for the company and the treatment of heart failure.
The Cordella platform is a revolutionary patient management system that utilizes daily PA pressure and vital signs data to guide therapeutic management and improve patient outcomes. It is the first and only platform to offer comprehensive care using both implanted PA sensors and non-invasive vital sign monitoring in the comfort of a patient's home.
Dr. Liviu Klein, Section Chief of Advanced Heart Failure at the University of California San Francisco and national principal investigator of the PROACTIVE-HF trial, expressed excitement about this approval, stating that it has the potential to transform care for heart failure patients. He also highlighted how Endotronix's solution provides a more complete clinical picture of the patient, allowing providers to make informed decisions remotely between office visits.
More on illi News
The PROACTIVE-HF trial, which served as the basis for FDA approval, demonstrated impressive results with a low rate of heart failure hospitalization and all-cause mortality at 6 months. This further validates the effectiveness of Cordella in improving outcomes for heart failure patients.
In addition to providing critical PA pressure data through an implanted sensor, Cordella also offers other features such as seated PA pressure measurements with a handheld reader, patient visibility into key health trends, secure messaging between clinical teams and patients/caregivers, and reimbursement options through existing pathways.
Harry Rowland, CEO and co-founder of Endotronix, emphasized their belief in using innovation to drive excellence in patient care at home. He stated that this FDA approval is a major milestone for their company and the field of heart failure management. With this approval, they aim to extend optimal therapeutic management to more patients, keeping them out of the hospital and improving their quality of life.
More on illi News
Endotronix plans to launch Cordella in the U.S. later this year and has also submitted a dossier for CE Mark review, with a decision expected in 2025. The company's comprehensive solution, which combines implanted sensors and non-invasive vital sign monitoring, aims to engage patients, reduce congestion, and improve outcomes for those living with heart failure.
In conclusion, Endotronix's Cordella platform has received FDA approval for the treatment of heart failure, making it the first and only PA pressure-guided platform to offer comprehensive patient management at home. This approval is a significant achievement for the company and has the potential to transform care for heart failure patients. With its innovative features and proven results from clinical trials, Cordella is set to make a positive impact on the lives of those living with heart failure.
The Cordella platform is a revolutionary patient management system that utilizes daily PA pressure and vital signs data to guide therapeutic management and improve patient outcomes. It is the first and only platform to offer comprehensive care using both implanted PA sensors and non-invasive vital sign monitoring in the comfort of a patient's home.
Dr. Liviu Klein, Section Chief of Advanced Heart Failure at the University of California San Francisco and national principal investigator of the PROACTIVE-HF trial, expressed excitement about this approval, stating that it has the potential to transform care for heart failure patients. He also highlighted how Endotronix's solution provides a more complete clinical picture of the patient, allowing providers to make informed decisions remotely between office visits.
More on illi News
- 4-Star Gold Coast Hotel Showcases Chicago Artist's Watercolors
- Develop Africa Partners with Sierra Leonean Painter Sahr Songu Mbriwa to Raise Funds for Education
- Composer Andrew Prahlow to Perform Award-Winning Outer Wilds Soundtrack on Oct 17th at Brooklyn's Music Hall of Williamsburg
- Pineberry Manufacturing Inc. to Exhibit Automation Solutions at PACK EXPO International
- CostPredict Inc. Accepted for Participation in an Exclusive Tech Venture Accelerator Program
The PROACTIVE-HF trial, which served as the basis for FDA approval, demonstrated impressive results with a low rate of heart failure hospitalization and all-cause mortality at 6 months. This further validates the effectiveness of Cordella in improving outcomes for heart failure patients.
In addition to providing critical PA pressure data through an implanted sensor, Cordella also offers other features such as seated PA pressure measurements with a handheld reader, patient visibility into key health trends, secure messaging between clinical teams and patients/caregivers, and reimbursement options through existing pathways.
Harry Rowland, CEO and co-founder of Endotronix, emphasized their belief in using innovation to drive excellence in patient care at home. He stated that this FDA approval is a major milestone for their company and the field of heart failure management. With this approval, they aim to extend optimal therapeutic management to more patients, keeping them out of the hospital and improving their quality of life.
More on illi News
- Cell-Ed and National Minority Health Association Forge Strategic Partnership to Expand Caregiving and Health Equity Initiatives
- NEXT Door & Window Named Among Crain's 2024 Best Places to Work in Chicago
- Fortius Metals secures $2 Million Additional Funding to Bring Advanced Metal 3D Printing to the Aerospace and Defense Industry
- Voices Rising Festival Celebrates Diversity in E. Islip, GRAMMY Governor LACHI performs!
- Axtria Showcases AI-Powered Innovations at PMSA 2024 Fall Symposium USA - English India - English
Endotronix plans to launch Cordella in the U.S. later this year and has also submitted a dossier for CE Mark review, with a decision expected in 2025. The company's comprehensive solution, which combines implanted sensors and non-invasive vital sign monitoring, aims to engage patients, reduce congestion, and improve outcomes for those living with heart failure.
In conclusion, Endotronix's Cordella platform has received FDA approval for the treatment of heart failure, making it the first and only PA pressure-guided platform to offer comprehensive patient management at home. This approval is a significant achievement for the company and has the potential to transform care for heart failure patients. With its innovative features and proven results from clinical trials, Cordella is set to make a positive impact on the lives of those living with heart failure.
Filed Under: Business
0 Comments
Latest on illi News
- State of Nayarit Named the Official Mexican Tourism Destination of the Vancouver Canucks
- Naperville: Pilot Composting Drop-Off Program for Residents Begins Week of Oct. 7
- Chicago: MAYOR JOHNSON TRAVELS TO LONDON TO CHAMPION ECONOMIC GROWTH, GLOBAL BUSINESS, TOURISM & HOSPITALITY
- Joint Statement from Mayor Brandon Johnson and Chicago Board of Education Announcing Board Member Transition Plan
- Ribbon-Cutting Ceremony Marks the Completion of TAJ Flooring, Inc. Warehouse Facility Expansion
- ProtectVirginia Petitions Virginia Dept of Environmental Quality for Cruise Ship Regulations
- Campaign for Kindness: Floris UMC is bringing back respect, humility, and compassion this election season
- Situ Ve Offers a New Perspective on Love Amid the Rising Passport Bro Movement
- Sugar Grove Ace Celebrates 10th Anniversary with Community Event on October 12
- Mayor Brandon Johnson and the Chicago Department of Housing Secure $4 Million to Support Non-congregate Shelter Acquisition and Rehab
- Working Bikes Celebrates 25 Years Of Service To Chicago And The World
- Scout & Cellar Becomes First Winery in Texas to Receive B Corp Certification
- CRH Healthcare Acquires Four Urgent Care Clinics in Georgia
- Nora Restaurant & Bar Fall Specials
- eCaregivers Launches First-Ever Consumer-Driven Senior Care Platform for Private-Pay Home Care Offering Affordable, Full-Service Agency Experience
- Chris Dore Joins Bridge Legal as Managing Director, Strategic Opportunities
- Chicago: Mayor Brandon Johnson Launches "A Day in the Ward" to Strengthen Community Engagement, Underscore City Investments
- SomerCor Hosts Federal Elected and Government Officials to Showcase Hispanic Business Growth
- Culinary Star Carla Hall Set to Take Center Stage at National Restaurant Association Show® 2025
- Are You Ready To Join Team GOAT Today?